<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01129128</url>
  </required_header>
  <id_info>
    <org_study_id>10A1276</org_study_id>
    <nct_id>NCT01129128</nct_id>
  </id_info>
  <brief_title>Three Arm Trial of Immune Effects of Echinacea</brief_title>
  <official_title>3-arm Randomized Controlled Trial Assessing the in Vivo Effect of an Echinacea Purpurea on Immune Markers in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Washington</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine if either of two, commercially available, Echinacea
      purpurea products stimulate the immune system. For the study, 60 healthy adults will be
      randomized to receive one of the two Echinacea purpurea products or placebo for 10 days.
      Blood will be drawn to assess immune markers just before beginning the study medication,
      during the 10 day course of medication and after completing the course of medication. It is
      postulated that adults receiving either of the Echinacea products will have evidence of
      immune stimulation and those receiving placebo will not.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">March 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Level of TNF Alpha</measure>
    <time_frame>1-10 days after starting study medication</time_frame>
    <description>Highest level of TNF alpha while taking study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak Level IL-6</measure>
    <time_frame>1-10 days after starting study medication</time_frame>
    <description>Highest level of IL-6 while taking study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Level Interferon Gamma</measure>
    <time_frame>1-10 days after starting study medication</time_frame>
    <description>Highest level of Interferon gamma while taking study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Level IL-2</measure>
    <time_frame>1-10 days after starting study medication</time_frame>
    <description>Highest level of IL-2 while taking study medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1- 30 days after starting study medication</time_frame>
    <description>Adverse events such as nausea or rash in participants receiving an Echinacea formulation or placebo will be compared</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Upper Respiratory Tract Infections</condition>
  <arm_group>
    <arm_group_label>Echinacea preparation 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available Echinacea purpurea product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Echinacea preparation 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Commercially available Echinacea purpurea product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Echinacea purpurea product</intervention_name>
    <description>5 ml by mouth 3 times per day for 10 days</description>
    <arm_group_label>Echinacea preparation 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Echinacea purpurea product</intervention_name>
    <description>1 ml by mouth 3 times per day for 10 days</description>
    <arm_group_label>Echinacea preparation 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>either 5 ml or 1 ml by mouth three times per day for 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult (based on a screening health questionnaire)

          -  Speaks and reads English.

          -  If female of child-bearing potential, willing to use contraception to prevent
             pregnancy during the study.

          -  No use of any medication (other than multivitamins, essential fatty acids, oral
             contraceptives and probiotics) for 2 weeks prior to first dose of study.

          -  Willing to abstain from ingesting edible mushrooms for 2 weeks prior and throughout
             study.

          -  Willing to eat less than 2 garlic cloves per day for 2 weeks prior and during the
             study period

        Exclusion Criteria:

          -  Pregnancy or currently breastfeeding.

          -  History of autoimmune disease or immune disorders.

          -  History of asthma.

          -  History of allergic rhinitis.

          -  History of physician diagnosed eczema, psoriasis or other skin condition that could
             mask an Echinacea-induced rash.

          -  Known allergic reaction to Echinacea or related species, specifically ragweed
             (Ambrosia), chamomile (Matricaria), goldenrod (Solidago), and sunflower (Helianthus).

          -  Known allergic reaction to xylitol sweetener, glycerine, citric acid, or citrus fruits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Taylor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Washington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bastyr University</name>
      <address>
        <city>Kenmore</city>
        <state>Washington</state>
        <zip>98028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 14, 2010</study_first_submitted>
  <study_first_submitted_qc>May 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2010</study_first_posted>
  <results_first_submitted>May 4, 2012</results_first_submitted>
  <results_first_submitted_qc>May 4, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 5, 2012</results_first_posted>
  <last_update_submitted>June 14, 2012</last_update_submitted>
  <last_update_submitted_qc>June 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Washington</investigator_affiliation>
    <investigator_full_name>James Taylor</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Echinacea</keyword>
  <keyword>immune modulation</keyword>
  <keyword>prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Tract Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy adult volunteers enrolled from May 2010 through March 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
          <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
        </group>
        <group group_id="P2">
          <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
          <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
          <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
        </group>
        <group group_id="B2">
          <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
          <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="67"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.1" spread="10.6"/>
                    <measurement group_id="B2" value="35.1" spread="13.5"/>
                    <measurement group_id="B3" value="28.2" spread="8.0"/>
                    <measurement group_id="B4" value="32.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Level of TNF Alpha</title>
        <description>Highest level of TNF alpha while taking study medication</description>
        <time_frame>1-10 days after starting study medication</time_frame>
        <population>Data analyzed on any participant who TNF alpha level was obtained on 1 or more days while on study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
            <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
            <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Level of TNF Alpha</title>
          <description>Highest level of TNF alpha while taking study medication</description>
          <population>Data analyzed on any participant who TNF alpha level was obtained on 1 or more days while on study medication.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="436" spread="510"/>
                    <measurement group_id="O2" value="1467" spread="2330"/>
                    <measurement group_id="O3" value="721" spread="1272"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>comparison of peak level of TNF alpha after controlling for baseline level. Based on data from 20 participants in a group, there was a power of 0.9 to detect a difference of 1000 pg/ml with a standard deviation of 700 pg/ml</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels and performed log transformation of TNF alpha levels to account for skewed distribution of values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-173</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>comparison of peak level of TNF alpha after controlling for baseline level. Based on data from 20 participants in a group, there was a power of .9 to detect a difference of 1000 pg/ml with a standard deviation of 700 pg/ml</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels and performed log transformation of TNF alpha levels to account for skewed distribution of values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>705</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Level IL-6</title>
        <description>Highest level of IL-6 while taking study medication</description>
        <time_frame>1-10 days after starting study medication</time_frame>
        <population>Data analyzed on any participant who IL-6 level was obtained on 1 or more days while on study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
            <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
            <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Level IL-6</title>
          <description>Highest level of IL-6 while taking study medication</description>
          <population>Data analyzed on any participant who IL-6 level was obtained on 1 or more days while on study medication.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16296" spread="37448"/>
                    <measurement group_id="O2" value="44901" spread="79868"/>
                    <measurement group_id="O3" value="28526" spread="61921"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels and performed log transformation of IL-6 levels to account for skewed distribution of values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15793</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels and performed log transformation of IL-6 levels to account for skewed distribution of values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>23472</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Level Interferon Gamma</title>
        <description>Highest level of Interferon gamma while taking study medication</description>
        <time_frame>1-10 days after starting study medication</time_frame>
        <population>Data analyzed on any participant who Interferon gamma level was obtained on 1 or more days while on study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
            <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
            <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Level Interferon Gamma</title>
          <description>Highest level of Interferon gamma while taking study medication</description>
          <population>Data analyzed on any participant who Interferon gamma level was obtained on 1 or more days while on study medication.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74" spread="122"/>
                    <measurement group_id="O2" value="146" spread="321"/>
                    <measurement group_id="O3" value="121" spread="292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels and performed log transformation of Interferon gamma levels to account for skewed distribution of values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-16</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.76</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels and performed log transformation of Interferon gamma levels to account for skewed distribution of values</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-12</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Level IL-2</title>
        <description>Highest level of IL-2 while taking study medication</description>
        <time_frame>1-10 days after starting study medication</time_frame>
        <population>Data analyzed on any participant who IL-2 level was obtained on 1 or more days while on study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
            <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
            <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Level IL-2</title>
          <description>Highest level of IL-2 while taking study medication</description>
          <population>Data analyzed on any participant who IL-2 level was obtained on 1 or more days while on study medication.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82" spread="79"/>
                    <measurement group_id="O2" value="148" spread="321"/>
                    <measurement group_id="O3" value="68" spread="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <method>Regression, Linear</method>
            <method_desc>controlled for baseline levels</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>39</param_value>
            <ci_percent>95</ci_percent>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
        <description>Adverse events such as nausea or rash in participants receiving an Echinacea formulation or placebo will be compared</description>
        <time_frame>1- 30 days after starting study medication</time_frame>
        <population>Participants who received at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
            <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O2">
            <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
            <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events as a Measure of Safety and Tolerability</title>
          <description>Adverse events such as nausea or rash in participants receiving an Echinacea formulation or placebo will be compared</description>
          <population>Participants who received at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>day 1 (first dose of study medication) through day 30</time_frame>
      <desc>Patients specifically inquired about adverse events on day 2, 3, 7, 10, 17 and 30 using 76-item questionnaire.</desc>
      <group_list>
        <group group_id="E1">
          <title>Commercially Available Echinacea Product #1 (5 ml/Dose)</title>
          <description>Echinacea purpurea product; 5 ml dose administered three times daily for 10 days</description>
        </group>
        <group group_id="E2">
          <title>Commercially Available Echinacea Product #2 (1 ml/Dose)</title>
          <description>Echinacea purpurea product; 1 ml dose administered three times daily for 10 days</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Inert liquid that is similar in appearance and taste to the active Echinacea products</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MOSES</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain/cramps</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Appetite: decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Appetite: increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Gas/indigestion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness/sedation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sleep: excessive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sleep: insomnia, restless</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Weakness/fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Thirst: increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash/hives</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Levels of TNF alpha, IL-6, IL-2 and Interferon gamma varied widely limiting chance of detecting differences.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>James A Taylor, MD</name_or_title>
      <organization>University of Washington</organization>
      <phone>206-616-1206</phone>
      <email>uncjat@uw.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

